Click here to view cell apoptosis assay products
×

Recombinant Human VEGFR3/FLT4 Protein (Fc Tag)

Uniprot : P35916
  • Cat.No.:PKSH031420

  • Expression host: HEK293 Cells

To Purchase PKSH031420

Size:
  • 100μg
Price: $732
Qty:

Description

Synonyms FLT-4;FLT-41;FLT41;LMPH1A;PCL;VEGF Receptor 3;VEGFR-3;VEGFR3
Species Human
Expression_host HEK293 Cells
Sequence Met 1-Ile 776
Accession NP_002011.2
Application Functional ELISA
Mol_Mass 111 kDa
AP_Mol_Mass 160&85&75 kDa
Tag C-hFc
Bio_Activity 1. Immobilized recombinant human VEGFR3 at 5 μg/ml (100 μl/well) can bind recombinant human VEGF-D at a linear range of 62. 5-2000 ng/ml.
2. Immobilized recombinant human VEGF-C at 10 μg/ml (100 μl/well) can bind recombinant human VEGFR3 at a linear range of 0.64-80 ng/ml.
3. Scatchard analysis showed the affinity constant (Kd) of recombinant human VEGF-C bound to recombinant human VEGFR3 was 1. 4 nM.

Properties

Purity > 97 % as determined by reducing SDS-PAGE.
Endotoxin level < 1.0 EU per μg of the protein as determined by the LAL method.
Storage Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
Shipping This product is provided as lyophilized powder which is shipped with ice packs.
Formulation Lyophilized from sterile PBS, pH 7.4
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Reconstitution Please refer to the printed manual for detailed information.

Background

Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.

Related Products

Citations

Reviews/Q&A

  • Show all
  • Reviews
  • Q&A
... Show All Show Less

People Also Bought

Apply for
*Product Name:
*Catalog Number:
*Name:
*Email:
*Message:
*Country:
*When will you use it?

*Captcha: